Adults 45 to 75, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Participants Completing CRC Screening Per Electronic Medical Record DocumentationPrimary· 12 months post-baseline interview
Number of participants completing CRC screening by any test (defined as colonoscopy or FIT) is measured by electronic medical record review. Dates that participants had a colonoscopy and dates of FIT analysis are extracted from the electronic medical record.
Group
Value
95% CI
Tailored DVD
37
Tailored DVD + Patient Navigation
59
Usual Care
27
Participants Completing Colonoscopy Per Electronic Medical Record DocumentationSecondary· 12 months post-baseline interview
Number of participants completing a colonoscopy is measured by electronic medical record review (EMR). Dates that participants completed a colonoscopy are extracted from the EMR.
Group
Value
95% CI
Tailored DVD
24
Tailored DVD + Patient Navigation
46
Usual Care
20
Bowel Preparation Quality Rating Using Boston Bowel Preparation ScaleSecondary· 12 months post-baseline interview
Participants quality of bowel preparation is measured by the endoscopist during their colonoscopy procedure using the Boston Bowel Preparation Scale (BBPS). BBPS scores the total quality on a 10 point scale from 0-9. Higher scores indicate better quality of bowel preparation.
Group
Value
95% CI
Tailored DVD
7.13
± 1.90
Tailored DVD + Patient Navigation
6.59
± 2.40
Usual Care
7.05
± 2.44
Participants With Adequate Quality of Bowel Preparation Per Modified Aronchick Rating ScaleSecondary· 12 months post-baseline interview
Participants quality of bowel preparation is measured by the endoscopist during their colonoscopy using a modification of the Aronchick rating scale. The Aronchick scale rates quality as 1=excellent, 2=good, 3=fair, or 4=poor. Some endoscopists choose to grade quality more generally as adequate vs. inadequate. To accommodate this variation, bowel preparation ratings have been dichotomized into adequate (excellent, good, fair, or adequate ratings) vs. inadequate (poor or inadequate ratings). Adequate is scored as 1 and indicates better quality of bowel preparation than inadequate which is score
Group
Value
95% CI
Tailored DVD
22
Tailored DVD + Patient Navigation
39
Usual Care
18
Colonoscopy-Related Procedural Anxiety for Participants Completing a ColonoscopySecondary· 12 months post-baseline interview
Colonoscopy-related procedural anxiety is measured by self-report using the 6-item short form of the State Anxiety Scale of the State-Trait Anxiety Inventory. Each item is scored from 1 to 4 (1=not at all; 4=very much so) with higher scores indicating greater anxiety.
Group
Value
95% CI
Tailored DVD
2.46
± 0.78
Tailored DVD + Patient Navigation
2.23
± 0.67
Usual Care
2.28
± 0.76
Satisfaction With Colonoscopy ExperienceSecondary· 12 months post-baseline interview
Satisfaction with the colonoscopy experience is measured by self-report using a single item developed by the research team. Satisfaction is rated from 1 to 4 where 1=not at all satisfied, 2=a little satisfied, 3=mostly satisfied, and 4=completely satisfied. Scores range from 1 to 4 with higher scores indicating greater satisfaction.
Group
Value
95% CI
Tailored DVD
3.38
± 0.96
Tailored DVD + Patient Navigation
3.60
± 0.78
Usual Care
3.13
± 1.06
Participants Completing a Fecal Immunochemical Test (FIT) Per Electronic Medical Record DocumentationSecondary· 12 months post-baseline interview
Number of participants completing a FIT is measured by electronic medical record review (EMR). Dates of FIT analysis are extracted from the EMR.
Group
Value
95% CI
Tailored DVD
15
Tailored DVD + Patient Navigation
13
Usual Care
8
Participants Who Self-Reported Completing CRC ScreeningSecondary· 6-9 months post-baseline interview
Number of participants who reported completing CRC screening by any test (defined as colonoscopy or FIT) during the 6 or 9 month post-baseline telephone interview.
Group
Value
95% CI
Tailored DVD
48
Tailored DVD + Patient Navigation
59
Usual Care
43
Participants Who Self-Reported Completing a ColonoscopySecondary· 6-9 months post-baseline interview
Number of participants who reported completing a colonoscopy during the 6 or 9 month post-baseline telephone interview.
Group
Value
95% CI
Tailored DVD
26
Tailored DVD + Patient Navigation
46
Usual Care
27
Participants Who Self-Reported Completing a Fecal Immunochemical Test (FIT)Secondary· 6-9 months post-baseline interview
Number of participants who reported completing a FIT during the 6 or 9 month post-baseline telephone interview.
Group
Value
95% CI
Tailored DVD
34
Tailored DVD + Patient Navigation
28
Usual Care
20
Change in Knowledge of CRC and ScreeningSecondary· 6 months post-baseline interview
Change from baseline in knowledge of CRC and screening is measured at 6 months by self-report using a 9-item multidimensional scale. Each item is scored as 1=correct or 0=incorrect and summed to yield a scale score. Scores range from 0 to 9 with higher summated scores indicating greater knowledge of CRC and screening tests. The mean of the 9 items is calculated at baseline and 6 months post-baseline. Change from baseline equals the mean at 6 months minus the mean at baseline. Change can range from -9 to 9 with positive values indicating an increase in knowledge.
Group
Value
95% CI
Tailored DVD
1.14
± 0.24
Tailored DVD + Patient Navigation
1.32
± 0.25
Usual Care
0.75
± 0.23
Change in Perceived Risk for CRCSecondary· 6 months post-baseline interview
Change from baseline in perceived risk for CRC is measured by self-report at 6 months using a 3-item scale. We ask participants how likely it is that they will get colon cancer sometime during their lifetime, within the next 10 years, and within the next 5 years. Each item is scored from 1 to 4 (1=very unlikely; 4=very likely). Higher scores indicate a higher perceived risk for getting CRC. The mean of the 3 items is calculated at baseline and 6 months. Change in perceived risk equals the mean at 6 months minus the mean at baseline. Change can range from -3 to 3 with positive values indicating
Group
Value
95% CI
Tailored DVD
0.23
± 0.11
Tailored DVD + Patient Navigation
0.03
± 0.11
Usual Care
0.18
± 0.11
Sponsor's own description
The purpose of this study is to test different approaches to help people understand the purpose of colorectal cancer (CRC) screening, two screening test options available, and the barriers to screening so they can make informed decisions about CRC screening. Participants will be randomly assigned to one of three groups: (1) one group will receive a tailored digital video disc (DVD) in the mail; (2) another group will receive the mailed DVD plus telephone calls from a patient navigator; and (3) the third group will receive the care normally provided by the healthcare system's endoscopy department.
The investigators hypothesize the following: (1) participants who receive the tailored DVD plus the patient navigation intervention will have higher rates of CRC screening with the fecal immunochemical test (FIT), colonoscopy, or either screening test compared to those who receive the tailored DVD alone; (2) participants who receive either intervention (DVD only or DVD plus patient navigation) will have higher rates of CRC screening with FIT, colonoscopy, or either screening test than those who receive usual care; and (3) participants who receive either intervention who complete colonoscopy will have better quality of bowel preparation, less anxiety about the procedure, and greater satisfaction with the colonoscopy experience than those who receive usual care.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino
· Phase 3
· recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
· Phase 1, PHASE2
· recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
· Phase 1, PHASE2
· recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes
· recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes
· recruiting
Other Indiana University trials
Trials by the same sponsor.
NCT07470086 — The Role of Environmental Temperatures in Respiratory Control
· NA
· not yet recruiting
NCT07470099 — The Role of Breathing Perception in Respiratory Control
· NA
· not yet recruiting
NCT07179952 — Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA )
· Phase 2
· not yet recruiting
NCT07070804 — Maternal Biomarkers and Environmental Contributors to Autism Spectrum Disorders in Children of First-time Mothers
· not yet recruiting
NCT07499583 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder
· Phase 1, PHASE2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Indiana University
Last refreshed: 13 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03200366.